BTK and mantle cell lymphoma: Although both the SHINE and TRIANGLE trials utilized ibrutinib in the front-line setting, it is important to note that ibrutinib is no longer on the U.S. market for MCL, given the improved safety profile of acalabrutinib and zanubrutinib (acalabrutinib and zanabrutinib are FDA-approved for MCL; acalabrutinib is EMA approved for MCL); therefore, data from these studies will need to be extrapolated with the safety profile of the second generation BTK inhibitors in mind.